Important Information

Similar documents
Important Information

Cannabis for Medical Purposes

POLICY NUMBER: POL 153

Home Phone Cell Phone

Medicinal Cannabis. Patient Log Book. Record your cannabis use and find the right dose

Questionnaire 1 of 5: Cannabis Plant and Cannabis Resin. Introduction

Cannabinoids: access and symptom management in cancer

Recent trends in medical cannabis use in Canada

Marijuana Guidelines

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

This questionnaire will ask you about approved medical use of extracts and tinctures of cannabis at national level.

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

Life s brighter under the sun MEDICAL CANNABIS AND GROUP BENEFITS PLAN COVERAGE

HUSKY Health Benefits and Prior Authorization Requirements Grid* Behavioral Health Partnership Effective: January 1, 2012

CDHA 2016 Fall Symposium. Speaker Handout Files. For registered attendees only

HIV MANAGEMENT PROGRAMME APPLICATION FORM

LEGAL ASPECTS of MEDICAL MARIJUANA Florida Nurse Practitioner Network Annual Conference September 17, 2018

INITIAL PATIENT INTAKE FORM

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

PATIENT QUESTIONNAIRE

Section I. Short-acting opioid Prior Authorization Criteria

420 ADVISORY MANAGEMENT

Dr. Meldon Kahan. Women s College Hospital. with PIA LAW

COMPLETE DRUG AND ALCOHOL POLICY & Testing Policy

Marijuana Usage Guidelines 10/2017

Explanatory note for Operational Policy Manual (OPM) # , Cannabis for Medical Purposes

Patient Assessment Form

Health Care Professionals Forum. May 19, 2016

Stakeholder Consultation Results: Proposed Policy : Medical Aid Cannabis (Marijuana) for Medical Purposes

Medical Cannabis use in the Older Patient. Amanjot Sidhu, MD, FRCPC Division of Geriatric Medicine McMaster University

Updated: 08/2017 DMMA Approved: 11/2017

PATIENT INTAKE FORM. Name: Address: Town: State: Zip Code: MMJ Card #: Exp. Date: Drivers License #: Exp. Date: Home Phone: Cell:

Petitions to Add Qualifying Medical Conditions to the Medical Cannabis Program A REPORT TO THE COMMISSIONER OF HEALTH

Marijuana Usage Guidelines 4/2016

Marijuana and the Workplace : Changing Times

California. Prescribing and Dispensing Profile. Research current through November 2015.

Frequently Asked Questions

Medication Agreements Promoting awareness, dialogue and level-set expectations

CANNABIS LEGALIZATION: SUPPORT MATERIAL FOR MANITOBA PHYSICIANS

201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone.

Consumer Information Cannabis (Marihuana, marijuana)

General Information: (Circle One) (Circle One) Primary Insured's Information Skip if you are primary

REQUEST FOR MEDICARE PRESCRIPTION DRUG COVERAGE DETERMINATION This form may be sent to us by mail or fax:

CANADIAN CANNABIS CRAZE (AND CONUNDRUM) Dr. Melissa Snider-Adler Chief Medical Review Officer DriverCheck Inc. Addiction Medicine Physician

Billing WorkSafeBC for

APPLICATION FOR Page 1/8 RESIDENTIAL TREATMENT

OPIOID PRESCRIBING RULES

Prescribing and Dispensing Drugs

The products being taken by children with epilepsy are not the equivalent of the marijuana widely used for recreational purposes.

What is Quitline Iowa?

What do you need to know about CANNABIS. Answers to some of your questions.

Legalization of Recreational Cannabis. Mary Ellen Bench City Solicitor, City of Mississauga November 26, 2018

Regulatory Considerations for Legalized Marijuana. Nick Brechun, Colorado Julie Quinn, Minnesota

Medical Marijuana Update Chris Belletieri, DO

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Patient consent to disclose personal health information (PHI) form

New Patient Information

FLOWTUSS (hydrocodone bitartrate and guaifenesin) oral solution OBREDON (hydrocodone bitartrate and guaifenesin) oral solution

Faculty/Presenter Disclosure

These documents were created to support the work of the Coalition of Colorado Campus Alcohol and Drug Educators. We welcome prevention teams at

Section: Claims Payment - Cognitive Services (PAS Policy Administered by Drug Plan and Extended Benefits Branch)

/ / Please provide contact information and indicate ONE method of preferred contact for notification of the results: me at:

CORONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW

Medical Marijuana Use in the Workplace

99 SOUTH ALCANIZ STREET SUITE B PENSACOLA, FL

HOSPICE INFORMATION FOR MEDICARE PART D PLANS

Public Policy Agenda 2016

A new model for prescribing varenicline

Prescription Monitoring Program (PMP)

Controlled Substance and Wellness Agreement

MODIFICATION OF APPLICATION TO BECOME A LICENSED PRODUCER UNDER THE ACCESS TO CANNABIS FOR MEDICAL PURPOSES REGULATIONS

Marijuana: The Facts

January 19, Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9

Are We All Going to Pot?: Legal Issues Arising from Cannabis-Industry Growth The Canadian Perspective

RI Health Plan 2018 Annual Report Form on Tobacco Cessation Benefits

Drug Overdose Morbidity and Mortality in Kentucky,

PATIENT QUESTIONNAIRE

Referral to the Women s Alcohol and Drug Service (WADS) Procedure

8 Key Findings from the 2018 Community Cannabis Survey

Long Term Services Division. Supersedes: Policy Governing Behavior Support Service Planning, 1/19/96 and LTSD Behavior Support Policy Revision 6/23/00

Medical Marijuana Consent Form

The Salvation Army Homestead

Women s consent to treatment and storage form (IVF and ICSI)

PATIENT REGISTRATION Form

Use of Cannabinoids in Medical Practice

The federal legislation, Cannabis Act that legalizes recreational cannabis comes into effect on October 17, 2018.

Explanatory Notes Relating to Regulatory and Legislative Proposals Relating to the Taxation of Cannabis

Medical Cannabis MATT WEBSTER DO, MS

Attending Physician Statement - Severe asthma

NEW PROVIDER ENROLLMENT FOR ADULT SITE

Analgesics: Management of Pain In the Elderly Handout Package

March 12, Medical Marijuana Preliminary Consultation Online Survey Report and Analysis. Introduction:

Employee Substance Abuse Program

Medical Marijuana and the Workplace: Human Rights Considerations for ONA Members

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL

PREFACE. Saskatchewan is participating in the Common Drug Review (CDR).

OREGON MEDICAL MARIJUANA ACT

This page is for information. Do not submit.

Transcription:

Important Information Please work through the following pages with your patient or the patient s chart as necessary. Fax completed documents to 1 888 629-4722. Keep the original in your chart / file. Fee: upon receiving the completed booklet, WorkSafeNB will pay the booklet completion fee equivalent to twice the amount of an office visit fee. Each section must be complete to qualify for reimbursement by WorkSafeNB. If you do not wish or are unable to complete the booklet and wish to stop after question 2, please submit this completed receipt and pg. 1 of the Monitoring Form for Continued Use of Medicinal Cannabis and WorkSafeNB will pay the administration fee equivalent to 33% of an office visit fee. THIS DOCUMENT IS YOUR RECEIPT. I, request full reimbursement for completing the Cannabis Review booklet for my patient,. I, decline to complete the Monitoring Form for Continued Use of Medicinal Cannabis for my patient,. I have completed the administrative questions on the first page of the booklet and am requesting the appropriate reimbursement for administrative fees. Physician name: Signature: Date: Payee Code: For QUESTIONS on completing this form please contact WorkSafeNB toll-free at 1 877 647-0777. Please note: The information requested is based upon a reasonable standard of medical practice in the province of New Brunswick. The review process was developed according to the guidelines of WorkSafeNB s Cannabis (Marijuana) for Medical Purposes policy, available online at worksafenb.ca/info/cannabis-policy.

MONITORING FORM FOR CONTINUED USE OF MEDICINAL CANNABIS FAMILY PHYSICIAN/NURSE PRACTITIONER WorkSafeNB will review injured workers treatment plans and goals to ensure medicinal cannabis continues to be necessary and effective in treating the compensable injury or disease. We require the primary care provider or the authorizing physician to provide evidence of having followed WorkSafeNB s monitoring requirements. Patient name: 1. Are you this patient s: Primary Care Provider and/or Authorizing Physician 2. Do you agree to participate in WorkSafeNB s Cannabis Monitoring requirements by completing this form? WorkSafeNB first requests monitoring from the primary care provider. If the primary care provider does not agree to monitor the effects of the cannabis authorization, WorkSafeNB requests participation from the authorizing physician. If both care providers do not agree to participate, WorkSafeNB will not support further cannabis authorization as the safety and effectiveness of the treatment cannot be determined. 3. Please specify details of the medicinal cannabis authorization (if already provided): i. i a. This patient has medical authorization for grams of marijuana per day for duration. b. Mode(s) of administration: c. Document reported strains below: Strain % THC % CBD d. Cannabis brand or identifier: e. Licensed producer name:

4. Please list all current medications that you know to be prescribed or otherwise medically authorized for your patient, and include the dosage, schedule and indicated condition. (Please attach another page if more space is required) Current Medications Name of drug Dosage Schedule Indicated condition i. i iv. v. The following information is necessary for risk assessment or potential contraindications. 5. Please list any changes in the patient s medical condition you are aware of. Include all surgeries or procedures within that last year that you are aware of for this patient. (Please attach another page if more space is required) 6. Does your patient smoke tobacco? If, how much and how often? 7. Does your patient consume alcohol? If, how much and how often? 8. To your knowledge, does your patient currently use recreational drugs other than cannabis? If, please provide the substance and quantity: Page 2 of 4

9. Do any of the following apply to your patient to the best of your knowledge? Leave blank if unknown. i. They are under the age of 25 They have a personal history or strong family history of psychosis i They have a current or past cannabis use disorder iv. They have an active substance use disorder v. They have cardiovascular disease (angina, peripheral vascular disease, cerebrovascular disease, arrhythmias) vi. They have respiratory disease v She is a woman who is pregnant, planning to become pregnant, or breastfeeding vi They have a concurrent active mood or anxiety disorder ix. They smoke tobacco x. They have risk factors for cardiovascular disease xi. They are a heavy user of alcohol or is taking high doses of opioids, benzodiazepines or other sedating medications, whether prescribed or available over the counter 10. Do you have any concerns for your patient regarding side effects and/or adverse events associated with dried cannabis use? RISKS NE SOME UNSURE Unable to evaluate Medical/psychological side effects Cannabis dependence Driving impairment Ability to perform or function at work Ability to meet work site safety standards tasks Page 3 of 4

11. How has your patient s function changed since starting medicinal cannabis or since the date of the last review? 12. What are the revised functional goals of treatment using cannabis? Thank you for participating in WorkSafeNB s Cannabis Risk Assessment process. Page 4 of 4